Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    Alexandria, VA

    Search
    Alexandria, VA
    Show Map
    Map View
    Alexandria, VA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      208 Clinical Trials near Alexandria, VA

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Proton Therapy vs Photon Radiation for Esophageal Cancer

      Alexandria, Virginia
      This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather than x-rays) to send radiation inside the body to the tumor without damaging much of the healthy tissue around it. Intensity modulated photon radiotherapy uses high-energy x-rays to deliver radiation directly to the tumor without damaging much of the healthy tissue around it. It is not yet known whether proton beam therapy or intensity modulated photon radiotherapy will work better in treating patients with esophageal cancer.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Metastatic Disease, Active Malignancy, Others
      Must Be Taking:FOLFOX

      300 Participants Needed

      Rilvegostomig + Bevacizumab for Liver Cancer

      Arlington, Virginia
      This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disorders, Primary Malignancy, Others
      Must Not Be Taking:Steroids, Immunosuppressants, Anticoagulants, Others

      1220 Participants Needed

      KarXT for Alzheimer's-Related Psychosis

      Arlington, Virginia
      This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027, CN012-0056 or CN012-0034. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study, 14-week CN012-0056 or 14 week CN012-0034 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT and KarXT + KarX-EC in subjects with psychosis associated with Alzheimer's Disease.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:55 - 90

      Key Eligibility Criteria

      Disqualifiers:Severe Medical Conditions, Others

      800 Participants Needed

      Atogepant for Migraine Prevention

      Washington, District of Columbia
      This trial is testing a medication called Atogepant to see if it can safely and effectively prevent migraines in people who have them often. The medication works by blocking signals in the brain that cause migraines. Atogepant is a newly approved oral medication for the prevention of episodic migraine.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Hypertension, Suicidal Ideation, ECG Abnormalities, Others

      596 Participants Needed

      Adagrasib + Pembrolizumab for Lung Cancer

      Arlington, Virginia
      This trial tests two drugs, MRTX849 and pembrolizumab, in patients with advanced lung cancer who have a specific genetic mutation. MRTX849 targets the mutation to stop cancer growth, while pembrolizumab boosts the immune system to fight the cancer. The study aims to see how well these treatments work alone and together.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Active Brain Metastases, Seizures, Others
      Must Not Be Taking:Chemotherapy, Immune Checkpoint Inhibitors

      806 Participants Needed

      Erector Spinae Block for Post-Surgery Pain in Lung Cancer

      Washington, District of Columbia
      The aim of this study is to determine if erector spinae injections with bolus infusions with local anesthetic decrease postsurgical pain and opioid consumption in patients undergoing pulmonary resection surgery.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Pleurodesis, Decortication, Emergent Surgery, Others

      70 Participants Needed

      Heparin Dosing for Blood Clots and Heart Conditions

      Alexandria, Virginia
      The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Thrombophilia, ECMO, Others
      Must Be Taking:Heparin

      145 Participants Needed

      JUVÉDERM Products for Midface Volume Loss

      Arlington, Virginia
      The purpose of this study is to evaluate the safety and effectiveness of JUVÉDERM products in adults seeking improvement in facial volume and/or skin quality.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:22 - 65

      Key Eligibility Criteria

      Disqualifiers:Non-permanent Fillers, Loose Skin, Scarring, Others

      94 Participants Needed

      Combined Treatments for Facial Contouring

      Arlington, Virginia
      A study to evaluate overall participant satisfaction of face and neck appearance after treatment with onabotulinumtoxinA, JUVÉDERM® products, KYBELLA, CoolSculpting Elite, and select SkinMedica products in a diverse population.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:22 - 65

      Key Eligibility Criteria

      Disqualifiers:Myasthenia Gravis, Hypersensitivity, Facial Asymmetry, Others
      Must Not Be Taking:Weight Loss Medications

      130 Participants Needed

      Tezepelumab for Severe Asthma

      Washington, District of Columbia
      This trial tests an injectable medication called tezepelumab for people with severe asthma who need high doses of inhaled steroids and have frequent asthma attacks. The medication works by reducing inflammation in the airways to help improve breathing and decrease asthma attacks.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Severe COPD, Others
      Must Be Taking:ICS, LABA

      287 Participants Needed

      Faricimab for Diabetic Macular Edema

      Oxon Hill, Maryland
      This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Untreated Diabetes, Active Cancer, Stroke, Others
      Must Be Taking:Insulin, Anti-hyperglycemics

      218 Participants Needed

      Blood Thinners for Pulmonary Embolism Prevention After Hip and Knee Replacement

      Alexandria, Virginia
      PEPPER is a randomized study comparing the three most commonly used anticoagulants in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery. The anticoagulants being compared are enteric coated aspirin, low intensity warfarin, and rivaroxaban.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:21+

      Key Eligibility Criteria

      Disqualifiers:Bilateral Replacement, Hemorrhage, Hypertension, Others
      Must Not Be Taking:Chronic Anticoagulants

      20000 Participants Needed

      MZE829 for Kidney Disease

      Arlington, Virginia
      This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Transplantation, Cancer, Bariatric Surgery, Diabetes, Others

      56 Participants Needed

      Adipose Tissue Allograft for Knee Arthritis

      Oxon Hill, Maryland
      The purpose of this study is to evaluate the safety profile of BRC-OA for pain treatment in patients with mild to severe OA of the knee, focusing particularly on two distinct doses. Alongside safety assessments, the study also aims to investigate the initial efficacy of BRC-OA in treating pain among these patients. The study product is a cryopreserved devitalized adipose tissue allograft (BRC-OA). BRC-OA is composed of a devitalized human adipose particulate that retains the inherent properties of adipose such as tissue architecture, extracellular matrix, and signaling molecules.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:BMI > 40, Knee Surgery, Others
      Must Not Be Taking:Anticoagulants, Immunosuppressives, Marijuana, Others

      42 Participants Needed

      RAS(ON) Inhibitors for Gastrointestinal Cancer

      Fairfax, Virginia
      The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Tumors, Impaired GI Function, Others

      1130 Participants Needed

      VH3810109 + Cabotegravir for HIV

      Washington, District of Columbia
      This trial tests a new drug, VH3810109, given with an enzyme to help absorption, combined with cabotegravir shots in adults with controlled HIV who are already on treatment.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Skin Disorders, Cirrhosis, Others
      Must Be Taking:Antiretrovirals

      128 Participants Needed

      Tranexamic Acid for Postpartum Hemorrhage

      Washington, District of Columbia
      In part 1 of the study, the investigators conducted a prospective, open-label, dose finding pharmacokinetic (PK) study in 43 pregnant 3rd trimester women scheduled for non-emergent cesarean section. The investigators administered three doses of the drug (5 mg/kg, 10 mg/kg and 15 mg/kg) in an escalating fashion by cohort with the lowest dose first. The drug was administered intravenously at the time of umbilical cord clamping for a non-emergent cesarean section. A maximum of 1 gram was administered. TXA serum levels at several time points after delivery were assayed to see if they reach the target plasma concentration of 10 microg/mL. A PK model was constructed for determining the optimal TXA dose administered at parturition. In part 2 of the study, the investigators aim to compare PKPD endpoints using prophylactic TXA via IV and IM routes administered pre-cord clamp. The investigators will administer 1000 mg TXA within 10 minutes of skin incision via intravenous infusion (up to n=15), intravenous bolus \< 2 minutes (up to n=15) and intramuscular injection (up to n=15). The investigators will target women undergoing scheduled cesarean delivery greater than 34 weeks gestation, women undergoing vaginal delivery \> 34 weeks of gestation and morbidly obese women (BMI\>=40) undergoing either a vaginal or cesarean delivery. The investigators will use advanced modeling techniques to determine time to achieve PKPD targets and duration remaining at those targets. The goal will be to determine how the optimal dose may vary if route of administration is modified. The investigators plan to enroll 45 patients in addition to the 43 that were enrolled during part 1. Our goal is to 30 participants, but the investigators will enroll 45 to account for lost to follow-up. The investigatorsalso aim to enroll 30 patients undergoing vaginal delivery and 30 morbidly obese women (BMI \> 50) undergoing either a vaginal or cesarean delivery but the investigators will enroll 45 patients for each of these groups to account for loss to follow up. In addition, the investigators will enroll 30 pregnant patients receiving no medication acting as the control group, but the investigators will enroll 45 to account for loss to follow up.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 50
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Thromboembolic Disease, Seizure Disorder, Renal Dysfunction, Others
      Must Not Be Taking:Anti-fibrinolytics

      120 Participants Needed

      Stereotactic Radiation + Immunotherapy for Kidney Cancer

      Alexandria, Virginia
      This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread from where it first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Autoimmune Disease, Hypertension, Heart Failure, Others
      Must Be Taking:Immunotherapy

      240 Participants Needed

      Cabozantinib + Nivolumab for Advanced Skin and Head & Neck Cancers

      Alexandria, Virginia
      This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine how quickly patients can be divided into groups based on biomarkers in their tumors. A biomarker is a biological molecule found in the blood, other body fluids, or in tissues that is a sign of a normal or abnormal process or a sign of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. The two biomarkers that this trial is studying are "tumor mutational burden" and "tumor inflammation signature." Another purpose of this trial is to help doctors learn if cabozantinib and nivolumab shrink or stabilize the cancer, and whether patients respond differently to the combination depending on the status of the biomarkers.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Organ Dysfunction, Autoimmune Disease, Others
      Must Not Be Taking:Anticoagulants, Steroids, CYP3A4 Inducers

      150 Participants Needed

      Broccoli Extract for Tobacco-Related Cancer Risk

      Washington, District of Columbia
      This trial tests if an extract from broccoli seeds and sprouts can help heavy smokers by removing harmful substances from their bodies and protecting their cells from damage. Sulforaphane, derived from broccoli seeds and sprouts, has been shown to induce detoxification enzymes and protect against cancer.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Invasive Cancer, HIV, Hepatitis B, Others
      Must Not Be Taking:Anti-retrovirals, Anti-neoplastics

      135 Participants Needed

      Why Other Patients Applied

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78
      Match to a Trial

      Tirabrutinib for Central Nervous System Lymphoma

      Washington, District of Columbia
      This trial is testing tirabrutinib alone and with other cancer drugs in patients with PCNSL. It targets those who haven't responded to previous treatments or are newly diagnosed. Tirabrutinib works by blocking a protein that helps cancer cells grow. Tirabrutinib was approved for use in treating primary central nervous system lymphoma.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Severe Heart, Severe Lung, Others
      Must Not Be Taking:Anticoagulants, Corticosteroids

      119 Participants Needed

      Chemotherapy + Radiation for HIV-Associated Anal Cancer

      Washington, District of Columbia
      This trial studies the effects of chemotherapy, radiation, and immunotherapy in treating HIV-associated anal cancer. It targets both low-risk and high-risk patients, aiming to kill cancer cells and help the immune system prevent the cancer from coming back.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Live Vaccines, Autoimmune Disease, Others
      Must Be Taking:Antiretroviral Therapy

      40 Participants Needed

      EG-70 for Bladder Cancer

      Washington, District of Columbia
      This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or inadequately treated.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Recent Malignancy, Renal Failure, Metastatic Disease, Others
      Must Not Be Taking:Chemotherapy, Pembrolizumab

      350 Participants Needed

      VT3989 for Mesothelioma

      Arlington, Virginia
      This trial tests a new drug, VT3989, for safety and effectiveness in patients with certain types of cancer that don't respond to other treatments. Researchers aim to find the best dose and see if the drug can help control the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active Brain Metastases, CNS Tumors, HIV, Others
      Must Not Be Taking:TEAD Inhibitors

      336 Participants Needed

      Green Tea for Prostate Cancer

      Alexandria, Virginia
      This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance. Green tea catechins may stabilize prostate cancer and lower the chance of prostate growing.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:21+

      Key Eligibility Criteria

      Disqualifiers:Renal Disease, Hepatic Disease, Metastases, Others
      Must Not Be Taking:Hormone Therapy, Chemotherapy

      360 Participants Needed

      Apalutamide for Prostate Cancer

      Washington, District of Columbia
      Apalutamide is an anti-androgen that blocks the effect of testosterone on prostate cancer growth. This phase IIa trial is designed to determine whether very low doses of apalutamide, given for 3 to 4 weeks before prostate surgery to men with prostate cancer confined to the prostate gland, reduces plasma levels of PSA (a biomarker of apalutamide's ability to block testosterone). If low dose apalutamide lowers PSA levels in this setting, further study of this agent in men with localized prostate cancer who wish to delay definitive therapy with surgery or radiation may be warranted.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Metastases, Neuroendocrine Differentiation, Seizure, Others
      Must Not Be Taking:Antiandrogens, Estrogens, Antipsychotics, Others

      34 Participants Needed

      DAS-001 for Myasthenia Gravis

      Washington, District of Columbia
      This trial tests whether adding ondansetron to pyridostigmine can help patients with myasthenia gravis who suffer from stomach problems caused by pyridostigmine. Pyridostigmine helps muscles work better, but it can cause nausea. Ondansetron is used to prevent this nausea. The goal is to see if patients can tolerate higher doses of pyridostigmine without feeling sick. Ondansetron is widely used to prevent nausea and vomiting in various conditions, including chemotherapy, pregnancy, and postoperative recovery.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:GI Diseases, Hepatic, Renal, Others
      Must Be Taking:Pyridostigmine

      24 Participants Needed

      BCG + N-803 for Bladder Cancer

      Alexandria, Virginia
      This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Muscle-invasive Cancer, HIV, CHF, Others
      Must Be Taking:BCG Therapy

      596 Participants Needed

      Zelenectide Pevedotin for Non-Small Cell Lung Cancer

      Arlington, Virginia
      This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one line of therapy in the advanced/metastatic setting (see inclusion criteria below). The study will comprise of 2 cohorts: Cohort A (non-squamous NSCLC) and Cohort B (squamous NSCLC).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:SCLC, CNS Metastases, Diabetes, Others
      Must Not Be Taking:MMAE, Steroids, CYP3A Inhibitors, Others

      73 Participants Needed

      RO7790121 for Eczema

      Arlington, Virginia
      The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Other Skin Conditions, Active Infection, Others
      Must Not Be Taking:Corticosteroids, Calcineurin Inhibitors

      160 Participants Needed

      1...345...7

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do clinical trials in Alexandria, VA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Alexandria, VA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Alexandria, VA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Alexandria, VA is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Alexandria, VA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Alexandria, VA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Alexandria, VA?

      Most recently, we added BI 764198 for Focal Segmental Glomerulosclerosis, Enlicitide + Rosuvastatin for High Cholesterol and ELAPR002f Gel for Acne Scars to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in Virginia

      Anxiety Clinical Trials in Virginia

      Schizophrenia Clinical Trials in Virginia

      ADHD Clinical Trials in Virginia

      Bipolar Disorder Clinical Trials in Virginia

      Multiple Sclerosis Clinical Trials in Virginia

      Autism Clinical Trials in Virginia

      Treatment Resistant Depression Clinical Trials in Virginia

      Borderline Personality Disorder Clinical Trials in Virginia

      Social Anxiety Disorder Clinical Trials in Virginia

      Parkinson's Disease Clinical Trials in Virginia

      Alzheimer's Disease Clinical Trials in Virginia

      By Location

      Clinical Trials near Richmond, VA

      Clinical Trials near Charlottesville, VA

      Clinical Trials near Norfolk, VA

      Clinical Trials near Fairfax, VA

      Clinical Trials near Roanoke, VA

      Clinical Trials near Falls Church, VA

      Clinical Trials near Virginia Beach, VA

      Clinical Trials near Newport News, VA

      Clinical Trials near Lynchburg, VA

      Clinical Trials near Chesapeake, VA

      Clinical Trials near Danville, VA

      Clinical Trials near Arlington, VA

      Other People Viewed

      By Subject

      18 Eczema Trials near Alexandria, VA

      177 Clinical Trials near Alexandria, LA

      127 Clinical Trials near Alexandria, MN

      221 Clinical Trials near Harrisonburg, VA

      216 Clinical Trials near Gainesville, VA

      Top Clinical Trials near Hampton, VA

      Top Clinical Trials near Fishersville, VA

      Top Clinical Trials near Bristol, VA

      Top Clinical Trials near Annandale, VA

      Top Clinical Trials near Charlottesville, VA

      Top Clinical Trials near Fort Belvoir, VA

      Top Clinical Trials near Christiansburg, VA

      By Trial

      Contingency Management for Tobacco Use Disorder

      2-HOBA for Alzheimer's Disease

      Referral Approaches for Tobacco Use

      Online Course for Dementia Caregivers

      Screening Models for Osteoporosis in Male Veterans

      Early Palliative Care for Multiple Myeloma and Lymphoma

      Gemcitabine + Vitamin C + Radiation for Pancreatic Cancer

      RGT001-075 for Type 2 Diabetes

      High-Dose-Rate Brachytherapy for Prostate Cancer

      Approach Avoidance Training for Alcohol Use Disorder

      Home Exercises vs Physical Therapy for Achilles Tendinopathy

      The Relational Playbook for Burnout

      Related Searches

      Top Clinical Trials near Alpena, MI

      Kisspeptin for Delayed Puberty

      Top Clinical Trials near Columbia, MO

      IOeRT for Breast Cancer

      Top Clinical Trials near Charlottesville, VA

      Trichostatin A for Blood Cancer

      Tofacitinib for Chronic Granulomatous Disease

      iROP DL for Retinopathy of Prematurity

      Artesunate for Idiopathic Pulmonary Fibrosis

      Amisulpride for Postoperative Nausea and Vomiting

      Habit-Based Counseling for Medication Adherence

      Long-term Safety of Lucerastat for Fabry Disease